NasdaqCM:CAPRBiotechs
Assessing Capricor Therapeutics (CAPR) Valuation After Positive HOPE-3 Data and Nippon Shinyaku Commercialization Deal
Capricor Therapeutics (CAPR) is back in focus after positive topline data from its Phase 3 HOPE-3 trial of Deramiocel for Duchenne muscular dystrophy, along with a new commercialization deal with Nippon Shinyaku.
See our latest analysis for Capricor Therapeutics.
The upbeat HOPE-3 data and the Nippon Shinyaku deal help explain why Capricor’s share price has surged to $27.81, with a roughly four week share price return near 380 percent and a one year total shareholder return above 110 percent...